Trial Profile
Intradermal Hepatitis-B-vaccination in non-responders after topical application of imiquimod 5%.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2010
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary) ; Hepatitis B vaccine recombinant (HBvaxPro)
- Indications Hepatitis B
- Focus Pharmacodynamics
- 04 Jun 2010 Results published in Vaccine.
- 04 Jun 2010 Status changed from recruiting to active, no longer recruiting.
- 16 Sep 2009 New trial record